PRE-LAUNCH · EARLY ACCESS
The biotech signals Bloomberg is too
big to notice.
Dilution detection wired into the FDA catalyst calendar. Insider buying cross-checked against rising short interest. Filings translated into plain English — across a deliberately fixed universe of 287 biotech names.
No spam · invites in waves · not investment advice
Every terminal races to cover 8,000 tickers.
We chose 287.
Coverage is a vanity metric. The moment a tool tries to watch everything, it watches nothing well. BioVista tracks a fixed, hand-picked universe of clinical-stage and commercial biotech — deeply — so every signal actually means something.
Smaller and accurate beats large and wrong.
≈ 1 in 28 public biotechs makes the cut. The rest is noise we deliberately leave out.
Three signals you won't find fused anywhere else.
Get in before launch.
Join the early-access list. Founding members get in first, lock early pricing, and help shape the 287.
No spam · invites in waves · not investment advice